Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Quest Diagnostics Inc. (DGX - Analyst Report), a leading provider of diagnostic information services, announced its takeover of ConVerge Diagnostic Services, LLC from Water Street Healthcare Partners, one of the prime investors in the health care industry. However, the financial terms of the acquisition are yet to be disclosed.

The acquisition is part of the five-point strategy announced by the company in 2012. The strategies intend to strengthen DGX's foothold in the core diagnostic information services business, drive operational excellence, restore growth, simplify the organizational structure and deliver disciplined capital deployment. The company expects to grow 1%-2% through its strategically aligned acquisitions.

ConVerge Diagnostic is a regional leader in women's health with good repute for customer service, medical expertise and innovation. It provides clinical, cytology and anatomic pathology testing services to patients, physicians and hospitals in New England.

The addition of ConVerge Diagnostic is expected to synergize perfectly with the Quest Diagnostic's business portfolio. The acquisition will extend the range of diagnostic information services for DGX, facilitating greater accessibility of patients in the region and enhancing better patient outcomes in the long run. The transaction paves the way for both the companies to discover new medical innovations that can spur better patient outcomes.

ConVerge  Diagnostic is the fourth laboratory acquisition of Quest Diagnostics in 2013 and the second in Massachussets, after the Jan 2013 acquisition of UMass Memorial Medical Center's clinical and anatomic pathology outreach laboratory businesses in Worcester, MA.

Following the acquisition, ConVerge Diagnostic will become a wholly-owned subsidiary of Quest Diagnostics. Its laboratory in Peabody, MA, and its patient service centers currently functioning in Massachusetts, New Hampshire and Connecticut will operate as part of Quest Diagnostic's national laboratory network. Eventually the ConVerge laboratory will be integrated into the one-of-a kind laboratory facility being built by Quest Diagnostics in Marlborough, Mass.

Following the announcement of the five-point strategy, Quest Diagnostics has been rigorously trying to pursue it for robust organizational excellence. As a part of its plan to remain focused on the core diagnostic information services business, DGX has already divested its non-core assets, selling its OralDNA dental diagnostics, HemoCue diagnostic products, Ibrutinib royalty rights and Enterix colorectal-cancer product businesses. The divestments have generated gross proceeds of $800 million, which in turn, has propelled enhanced shareholder value.  

On the hand, the strategy of delivering an effective capital deployment is being affected through cautious acquisitions made by Quest Diagnostics in 2013 including the Tennessee-based toxicology and clinical laboratory business of Concentra, a Humana business, and lab-related clinical outreach operations of Dignity Health in California and Nevada.

Quest expects the ConVerge acquisition to be neutral to adjusted earnings per share in 2013. It, however, expects the transaction to be modestly accretive to adjusted earnings in 2014.

DGX currently carries a Zacks Rank #3 (Hold). Other stocks that are worth a look  include LCA-Vision Inc. (LCAV - Snapshot Report), LHC Group, Inc. (LHCG - Snapshot Report), each of them carries a Zacks Rank #1 (Strong Buy), and AmSurg Corp. (AMSG - Analyst Report), carrying a Zacks Rank #2 (Buy). 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVEST TECH- ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%